Payment overview · 2025
General Payments
$2,140.19
120 reported records · 26 companies
Healthcare provider profile · identity verified
Brandy M. Dantzer, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FORT WAYNE, IN · NPI 1558505131
Verified facts
What the public records show
CMS Open Payments records show Brandy M. Dantzer, NP received $2,140.19 in general payments during 2025 across 120 reported records.
Tandem Diabetes Care, Inc. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Somavert, Tirosint.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tirosint as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tirosint by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 372 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOMAVERT as an associated drug or biological on 705 records involving 439 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Somavert by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $295.18 | 13.8% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $203.38 | 9.5% | 12 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $166.17 | 7.8% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$164.89 | 7.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $162.49 | 7.6% | 13 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $142.49 | 6.7% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.44 | 6.7% | 12 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $141.12 | 6.6% | 4 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $76.65 | 3.6% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.41 | 3.6% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $76.11 | 3.6% | 4 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $57.16 | 2.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.64 | 2.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.53 | 2.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.29 | 2.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.08 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.62 | 1.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $38.06 | 1.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.53 | 1.4% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $29.21 | 1.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.34 | 1.3% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.85 | 1.0% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $20.01 | 0.9% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $19.91 | 0.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.14 | 0.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.49 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,097.69 | 119 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $295.18 | 17 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $203.38 | 12 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $166.17 | 5 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $164.89 | 9 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $142.49 | 9 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $141.12 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $82.77 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.72 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.72 | 6 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $76.65 | 4 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $76.41 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $76.11 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.35 | 6 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $59.86 | 4 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $42.53 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.29 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $30.53 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.23 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 319 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 372 | exact normalized | Medicare Part D |
| SOMAVERT somavert |
2025 | Somavert | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tirosint tirosint |
2025 | Tirosint | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Tirosint open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Tirosint · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
319 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
372 | 94 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | SOMAVERT open payments reported associated product |
CMS Open Payments — General Payments 705 supporting records · 439 recipient NPIs · example record 1228794127 |
Somavert · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
87 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 112 |
| Ozempic | Semaglutide | 372 | 94 |
| Mounjaro | Tirzepatide | 319 | 64 |
| Metformin Hcl | Metformin Hcl | 304 | 92 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 273 | 93 |
| Jardiance | Empagliflozin | 212 | 62 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 210 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 187 | 54 |
| Novolog Flexpen | Insulin Aspart | 170 | 59 |
| Humalog Kwikpen U-100 | Insulin Lispro | 162 | 62 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 146 | 56 |
| Lisinopril | Lisinopril | 132 | 46 |
| Humalog | Insulin Lispro | 119 | 29 |
| Synthroid | Levothyroxine Sodium | 117 | 25 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 25 |
| Gabapentin | Gabapentin | 97 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 31 |
| Losartan Potassium | Losartan Potassium | 92 | 28 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 87 | 24 |
| Novolog | Insulin Aspart | 84 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 83 | 26 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 82 | 36 |
| Metformin Hcl Er | Metformin Hcl | 75 | 23 |
| Glipizide | Glipizide | 72 | 22 |
| Farxiga | Dapagliflozin Propanediol | 68 | 16 |
| Ezetimibe | Ezetimibe | 66 | 19 |
| Trulicity | Dulaglutide | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 58 | 26 |
| Glimepiride | Glimepiride | 57 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 16 |
| Humulin R U-500 | Insulin Regular, Human | 53 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 52 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 51 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 46 | 22 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Xyosted | Testosterone Enanthate | 34 | suppressed |
| Methimazole | Methimazole | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 30 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Victoza 3-Pak | Liraglutide | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 24 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 23 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 21 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Prolia | Denosumab | 18 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 16 | 11 |
| Levemir Flexpen | Insulin Detemir | 16 | 12 |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Somavert | Pegvisomant | 11 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,140.19 · 120 records | Tandem Diabetes Care, Inc. | AFREZZA, CRENESSITY, CREON, CRYSVITA, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Flector, GENOTROPIN, GVOKE HYPOPEN, INPEN SMART INSULIN DELIVERY SYSTEM, ISTURISA, JARDIANCE, JATENZO, Korlym, LEQVIO, Licart, MOUNJARO, MYCAPSSA, Ozempic, QUTENZA, REPATHA, SOMAVERT, STRENSIQ, TEPEZZA, TERIPARATIDE, TWIIST, TZIELD, Tirosint, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error